It had everything to do with not being in the EU. As you correctly say, there was a lot of flexibility in terms of negotiation regarding the vaccine. But also, as you correctly say most EU members opted for the ‘United’ approach. In this respect they were hampered by massive bureaucracy and inter-state competition for resources which impaired their decision making process. Even when presented with access to an effective and inexpensive vaccine, developed with British money and expertise, in which they had declined to invest heavily or place early contracts for, they actively maligned the vaccine in many quarters, misrepresenting the risk/benefit ratio and discouraging usage as exemplified by Macron’s stupid pronouncements. Had we still been in the EU would things have been different? Well, there would have been considerable pressure to conform to a united approach, and we probably would have done. But if we had acted as we in fact did , but as EU members , we could have been restrained by EU compliance and regulatory delays and possibly contracted differently and there is no guarantee the outcomes would have been the same. So outside the EU we had a very successful vaccine rollout. Within the EU we might still have done reasonably, but we certainly wouldn’t have done better and would most likely have done worse. Quite frankly, logically it’s a no-brainer.
Jerry.